Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 30, 1997

Primary Completion Date

August 31, 2002

Study Completion Date

August 31, 2002

Conditions
Kidney Cancer
Interventions
DRUG

Interleukin-2

High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC

Trial Locations (15)

10466

Our Lady of Mercy Medical Center, The Bronx

60153

Loyola University Medical Center, Maywood

94609

Summit Medical Center, Oakland

91010-3000

Cancer Center and Beckman Research Institute, City of Hope, Duarte

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

46202-5289

Indiana University Cancer Center, Indianapolis

02215

Beth Israel Deaconess Medical Center, Boston

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

03756-0002

Norris Cotton Cancer Center, Lebanon

28232-2861

Carolinas Medical Center, Charlotte

97213-2967

Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Chiron Corporation

INDUSTRY

lead

Loyola University

OTHER

NCT00003126 - Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer | Biotech Hunter | Biotech Hunter